SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.4
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$27.50

19 Dec
2024

-0.420

OPEN

$27.48

-1.50%

HIGH

$27.65

1,249,670

LOW

$27.30

TARGET
$27.972 1.7% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 107.4 108.9 xxx
DPS (cps) xxx 106.0 106.8 xxx
EPS Growth xxx - 26.4% 1.5% xxx
DPS Growth xxx 1.9% 0.7% xxx
PE Ratio xxx N/A 24.9 xxx
Dividend Yield xxx N/A 3.9% xxx
Div Pay Ratio(%) xxx 98.7% 98.0% xxx

Dividend yield today if purchased 3 years ago: 2.33%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.90

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx107.4
DPS All xxxxxxxxxxxxxxx106.0
Sales/Revenue xxxxxxxxxxxxxxx8,652.2 M
Book Value Per Share xxxxxxxxxxxxxxx1,648.8
Net Operating Cash Flow xxxxxxxxxxxxxxx1,071.5 M
Net Profit Margin xxxxxxxxxxxxxxx5.91 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx6.53 %
Return on Invested Capital xxxxxxxxxxxxxxx4.59 %
Return on Assets xxxxxxxxxxxxxxx3.53 %
Return on Equity xxxxxxxxxxxxxxx6.53 %
Return on Total Capital xxxxxxxxxxxxxxx4.68 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx101.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx661 M
Long Term Debt xxxxxxxxxxxxxxx3,854 M
Total Debt xxxxxxxxxxxxxxx4,515 M
Goodwill - Gross xxxxxxxxxxxxxxx8,502 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx645 M
Price To Book Value xxxxxxxxxxxxxxx1.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx579.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx6,604 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,496 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx198 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

24/10/2024

3

Neutral

$26.10

-5.09%

Sonic Healthcare's hosted an investor presentation and site tour of its Clinipath laboratory in Perth, WA with Macquarie analysts highlighting Sonic has the largest team of pathologists (circa 40) amongst private providers in the state.

Also, market share in WA is 40% against circa 30% nationally.

The broker reports management expects margins to be supported by medicare indexation, increased specialist testing, and private fees/commercial testing opportunities.

Also: the Franklin.ai prostate biopsy algorithm is expected to be applied to processes and available for sale globally in 2025 following final trials.

Neutral. Target $26.10.

FORECAST
Macquarie forecasts a full year FY25 dividend of 108.00 cents and EPS of 106.00 cents.
Macquarie forecasts a full year FY26 dividend of 107.00 cents and EPS of 125.00 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

11/12/2024

3

Neutral

$29.04

5.60%

Sonic Healthcare has announced the acquisition of LADR Lab Group in Germany for -EUR423m with the scrip part (under escrow) representing circa 2.7% of Sonic's capital.

The broker has not been able to replicate management's projections for EPS accretion and has thus instead lifted forecasts by smaller percentages of 1.4%, 4.8% and 5.7% respectively for the next three years.

Higher risk-free rate assumptions have weighed down the increase in valuation, with the price target lifting by 3.5% to $29.04. Neutral.

The acquired business runs on lower margins, also because of medical supplies and logistical services and it probably means Sonic Healthcare can no longer purchase any more businesses in Germany, but Poland will be in focus now, the broker suggests.

FORECAST
Jarden forecasts a full year FY25 dividend of 109.50 cents and EPS of 114.50 cents.
Jarden forecasts a full year FY26 dividend of 118.30 cents and EPS of 142.40 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

1
Next Week At A Glance -16-20 Dec 2024

Dec 13 2024 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Dec 11, 2024

Dec 11 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Nov 21, 2024

Nov 21 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Oct 24, 2024

Oct 24 2024 - Daily Market Reports
5
Rudi’s View: Banks, Miners & Quality Small Caps

Sep 26 2024 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia